29 results about "Leonurine" patented technology

The present disclosure relates to a field of biomedical technology. Embodiments of the present disclosure provide a leonurine nanocomposite hydrogel and preparation method and application thereof, including: dissolving dopamine (DA) monomers and inducing oxidation and self-polymerization of the DA to obtain polydopamine (PDA) nanoparticles, grafting thiol polyethylene glycol folic acid (SH-PEG-FA) on a surface of the PDA nanoparticles to obtain folic acid polydopamine (FA-PDA) nanocarriers; loading a leonurine (Leon) using the FA-PDA nanocarriers of the step 1 to obtain FA-PDA@Leon; encapsulating the FA-PDA@Leon of the step 2 into a gel matrix to obtain gel@FA-PDA@Leon hydrogel.

The present invention relates to a composition for quickly reducing redness and repairing sensitive skin, belonging to the technical field of skin care products. The composition for quickly reducing redness and repairing sensitive skin comprises the following raw materials by mass parts: 20-30 parts of active substance gel, 0.2-0.5 part of collagen, 1-2 parts of glycerol, 0.5-0.7 part of Kochia scoparia, and 50-60 parts of water; the active substances in the active substance gel include 1.5-3 parts of N-acetylneuraminic acid, 1.2-2.5 parts of leonurine derivatives, and 1.2-1.5 parts of Acacia farnesiana extract. The in vitro cytotoxicity test of the composition for quickly reducing redness and repairing sensitive skin prepared by the present invention verifies its safety in vitro; when acting on the skin of patients with sensitive skin, it can significantly reduce swelling and relieve pain, and can achieve the purpose of repairing the skin barrier.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention relates to the field of modern pharmacy of traditional Chinese medicines, and discloses application of leonurine in preparation of antibacterial products. According to the invention, the in-vitro antibacterial activity of leonurine is detected by an agar dilution method and a broth trace dilution method. The result shows that the leonurine can inhibit the proliferation of a staphylococcus aureus standard strain, and also has an inhibiting effect on most of methicillin-sensitive staphylococcus aureus, methicillin-resistant staphylococcus aureus and methicillin-resistant coagulase-negative staphylococcus which are obtained by clinical separation; meanwhile, the leonurine can inhibit proliferation of a malassezia standard strain and a clinical isolated strain, also has an inhibiting effect on most of ketoconazole drug-resistant candida and ketoconazole dose dependence-sensitive candida obtained through clinical isolation, and can be used for preparing antibacterial pharmaceutical compositions and skin care products.

The invention discloses a leonurine hydrochloride and ursolic acid self-assembled nano preparation and application thereof in preparation of a medicine for treating acute lung injury. The invention provides a leonurine and ursolic acid self-assembled nano-preparation. The leonurine and ursolic acid self-assembled nano-preparation is obtained by self-assembling leonurine pharmaceutically acceptable salts and ursolic acid, wherein the amounts of the leonurine pharmaceutically acceptable salts and the ursolic acid are equal. The self-assembled nanoparticles have an obvious anti-lung inflammation effect, and the anti-inflammatory effect is obviously superior to that of a composition of the leonurine pharmaceutically acceptable salt and ursolic acid with the same dosage. Therefore, the leonurine and ursolic acid self-assembled nano preparation provided by the invention has the prospect of being developed into the medicine for treating the acute lung injury.

The invention relates to the technical field of functional antioxidants, in particular to a magnesium-based multi-level composite functional layer preparation method and application thereof.The magnesium-based multi-level composite functional layer preparation method comprises the steps that S1, superfine brucite is added with a tetrasilanol-water mixed solution for spraying, stirring is conducted at the temperature of 25-50 DEG C, then the temperature is increased to 80-100 DEG C for reaction, cooling and drying are conducted, silane hybridized brucite is obtained, and the molar mass ratio of silane to brucite is 0.5-2 mol: 10 kg; s2, adding a leonurine alcohol and water mixed solution into the silane hybridized brucite, spraying, dedusting and drying to obtain leonurus alkalized brucite; s3, adding piperlonguminol and water mixed solution into the motherwort alkalized brucite, spraying, stirring at 40-60 DEG C, heating to 100-120 DEG C, reacting, dedusting and drying to obtain cross-linked powder; and S4, adding a mixed solution of nano silicon dioxide and gamma-aminopropyltriethoxysilane into the cross-linked powder, stirring at 30-50 DEG C, and drying to obtain the composite functional layer. The composite functional layer prepared by the method can be used for visually monitoring the viscosity of the flame-retardant spray, has good flame-retardant synergism, is stably dispersed in the spray, is simple and environment-friendly in preparation process, is suitable for industrial production, and is suitable for various flame-retardant spray types.

The invention relates to the technical field of cell protection, and provides a cell protection solution, a protection method and application. The cell protection liquid comprises leonurine, human serum albumin and normal saline. The cell protection method comprises the following steps: S1, adding the human serum albumin into normal saline to prepare a cell preservation solution; s2, adding the leonurine into a cell preservation solution to prepare a cell protection solution; s3, resuspending and storing the collected mesenchymal stem cells or immune cells by using the cell protection liquid. The cell protection liquid is applied to mesenchymal stem cells and immune cells. According to the cell protection liquid, the protection method and the application provided by the invention, the cell activity can be maintained after mesenchymal stem cells and immune cells are prepared into a cell preparation, and the cell protection liquid has no toxic or side effect on the cells.

The invention relates to an alkaloid liposome, a preparation process thereof and an application of the alkaloid liposome in an external preparation, and belongs to the technical field of external preparations. The technical problem to be solved is to provide an alkaloid liposome technology which is higher in stability, safe and non-irritating. According to the scheme, the alkaloid liposome technology is characterized in that raw materials comprise alkaloid, hydrogenated lecithin, grease, polyhydric alcohols and water; the alkaloid is selected from at least three of piperine, tetrahydropiperine, tetrahydropalmatine, dihydrooat alkaloid D, caffeine and leonurine; the hydrogenated lecithin is selected from at least one of PHOSPHOLIPON80H or PhoslipTM HPC (Hydroxyethyl Propyl Phosphatidylcholine). The liposome is good in stability and low in irritation, and has the effects of promoting local tissue microcirculation, reducing choked flow rate, increasing local body temperature, enhancing tissue metabolism and improving local inflammation when being externally applied to skin.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded nano-micelle as well as a preparation method and application thereof. According to the invention, bromoalkanes with different chain lengths are introduced to a leonurine phenolic hydroxyl group by adopting a total synthesis method to prepare a leonurine derivative, and the drug-loaded nano-micelle is prepared by applying triptolide (TP) and the leonurine derivative. The embodiment of the invention verifies that the drug-loaded nano-micelle can reduce in-vivo and in-vitro toxicity caused by triptolide and improve the treatment effect on a mouse arthritis model induced by type II collagen. The novel triptolide compatible medicine prepared by the invention is small in toxic and side effects and has a good curative effect on rheumatoid arthritis.

The invention belongs to the technical field of motherwort planting, and particularly relates to a method for adjusting the content of active ingredients in motherwort plants, and indoleacetic acid is applied to motherwort. According to the invention, indoleacetic acid is applied to leonurus, so that the content of active ingredients in the leonurus, such as any one of rutin, leonurine, caffeic acid and ferulic acid, is increased.

Researches find that leonurine can up-regulate the expression of fat mass and obesity-related protein FTO in a myocardial fibrosis model mouse so as to activate the expression of a tumor inhibition factor p53, so that the inhibition of CFs cell proliferation, migration and fibrosis activation in the myocardial fibrosis model mouse is realized, and the leonurine has a good treatment effect on myocardial fibrosis. And due to up-regulation of FTO, the adverse effect of obesity factors on myocardial fibrosis can be inhibited to a certain extent.

The application relates to the technical field of cell protection, and provides a cell protection solution, a protection method and application. The cell protection solution comprises leonurine, human serum albumin and physiological saline. The cell protection method comprises the following steps: S1, adding the human serum albumin into physiological saline to prepare a cell preservation solution; S2, adding the leonurine into the cell preservation solution to prepare a cell protection solution; and S3, resuspending and preserving collected mesenchymal stem cells or immune cells by using the cell protection solution. The cell protection solution is applied to mesenchymal stem cells and immune cells. The cell protection solution, the protection method and the application can maintain cell activity after mesenchymal stem cells and immune cells are prepared into cell preparations and have no toxic side effects on the cells.

Disclosed herein are pharmaceutical compositions and uses thereof in treating Parkinson's disease. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4,5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

The invention discloses Qinggongning granules and a quality detection method thereof, and relates to the technical field of medicine detection. The Qinggongning granules are prepared from 11 medicines such as angelica sinensis, ligusticum wallichii and scalded peach kernels, and a quality detection method of the Qinggongning granules comprises the following steps: performing quantitative analysis of multi-components by single marker by taking aesculetin as an internal standard substance, establishing relative correction factors of liquiritin, calycosin-7-glucoside, amygdalin and leonurine hydrochloride, and calculating the content of each component in the Qinggongning granules through the relative correction factors. The Qinggongning granule quality detection method provided by the invention has the advantages of high practicability, simplicity in operation, low detection cost and accurate and reliable detection result, overcomes the singleness of Qinggongning granule quality control, provides a new way for Qinggongning granule quality evaluation, and has wide application prospects. The method has important significance in enhancing the overall quality control of Qinggongning granules and ensuring the clinical curative effect of the Qinggongning granules.

The invention discloses an exosome preparation for treating premature ovarian failure, and belongs to the technical field of biology. And adding leonurine and estradiol into the umbilical cord mesenchymal stem cell culture solution, and co-culturing to prepare the exosome preparation for treating premature ovarian failure. The conventional exosome and the leonurine and estradiol co-cultured exosome with the same dosage can weaken the inhibition effect of the 4-OHCP on the KGN cell activity, and the leonurine and estradiol co-cultured exosome has a better human ovarian granular cell damage repair effect than the conventional exosome. When the leonurine and estradiol co-cultured exosome is used for treating a rat with premature ovarian failure, inflammatory cell infiltration in ovarian tissue interstitial substances is improved, follicle granular cell layers are increased, follicles in the growing period are increased, and mature follicles develop. Compared with a premature ovarian failure model group, the leonurine and estradiol co-cultured exosome group has the advantages that the serum FSH and LH levels of rats are reduced, the AMH level is increased, and the treatment effect on the premature ovarian failure rats is superior to that of a conventional exosome group.

The invention discloses a construction method of a fingerprint spectrum of Shenkun blood nourishing granules and the fingerprint spectrum of the Shenkun blood nourishing granules, and belongs to the technical field of traditional Chinese medicine detection. Different batches of Shenkun blood nourishing particles are adopted to prepare a test solution; the preparation method comprises the following steps: preparing a single reference substance solution from reference substances of tanshinol, leonurine hydrochloride, syringin, protocatechualdehyde, caffeic acid, calycosin-7-O-beta-D-glucoside, lobetyolin, formononin, rosmarinic acid, alkannic acid, luteolin and kaempferol; respectively performing high performance liquid chromatography and high resolution mass spectrometry on the test solution and the reference substance solution, totally screening 18 characteristic peaks, and totally identifying 12 chemical components through standard substance comparison and fragment information analysis to obtain the fingerprint spectrum of the Shenkun blood nourishing granules. The fingerprint spectrum of the Shenkun blood-nourishing granules established by the method can be used for quality control detection of the Shenkun blood-nourishing granules, is beneficial to comprehensive monitoring of product quality, and ensures consistency, controllability and stability of the product quality.

The invention belongs to the technical field of traditional Chinese medicine quality control methods, and relates to a quality control method for traditional Chinese medicine motherwort in different harvesting periods. The quality control method comprises the following specific steps: preparation of a test solution, preparation of a mixed reference solution and a determination method, wherein a chromatographic column adopts a C18 column; a mobile phase is a methanol-10 [mu] mol / L ammonium acetate aqueous solution, gradient elution is carried out for 0-20 min, and methanol is 45%-100%; the flow velocity is 1.0 mL / min; the detection wavelength is as follows: the wavelength of quercetin, kaempferol and luteolin is 254 nm, and the wavelength of leonurine is 280 nm; the column temperature is 30 DEG C; the sample size is 5 microliters. According to the method disclosed by the invention, drug effects are taken as guidance, the screened chemical components quercetin, kaempferol, luteolin and leonurine not only can reflect the overall drug effects of medicinal materials, but also have part specificity, so that not only can the problem of disordered composition of medicinal parts caused by nonstandard harvesting time be solved, but also accurate association of'component-drug effects-quality 'can be realized, and the method is suitable for popularization and application. The method has important theoretical value and practical significance for guaranteeing the quality stability and the clinical curative effect reliability of the motherwort herb.

The application discloses an alkaloid liposome and a preparation process and application thereof in external preparations, and belongs to the technical field of external preparations. The technical problem to be solved is to provide an alkaloid liposome technology with higher stability and safety and no irritation. The scheme points are that raw materials include alkaloids, hydrogenated lecithin, oil, polyhydric alcohol and water; the alkaloids are selected from at least three kinds of piperine, tetrahydropiperine, fumarine, dihydroavenanthramide D, caffeine and leonuride; the hydrogenated lecithin is selected from at least one of PHOSPHOLIPON 80H or Phoslip HPC. The liposome has good stability and low irritation, and has the effects of promoting local tissue microcirculation, reducing resistance, improving local inflammation, improving local body temperature, enhancing tissue metabolism and the like when being used externally on the skin.

The invention discloses a method for simultaneously identifying stachydrine hydrochloride and leonurine. The method comprises the following steps: preparing a test solution, preparing a reference solution and identifying according to a thin-layer chromatography. The preparation of the test sample solution comprises the following steps: dissolving a test sample in methanol, heating and refluxing, evaporating the filtrate to dryness, adding hydrochloric acid into the obtained residue for dissolving, loading on a cation exchange resin column, eluting with a mixed solution, collecting the eluent, and evaporating to dryness to obtain the test sample solution. A preparation method of the mixed solution comprises the following steps: mixing 15-30 ml of stronger ammonia water, 2-4 g of sodium chloride and 70 ml of absolute ethyl alcohol, and adding water to 100 ml. According to the method, the test sample is prepared through elution of the mixed solution, the stachydrine hydrochloride and the leonurine can be separated and identified at the same time by combining elution of the cation exchange column and regulation and control of all parameters, the color development is clear, the operation is simple and convenient, the separation effect is good, the sample treatment time can be shortened to 4.5 h, the detection efficiency is improved, and the detection cost is reduced. The method can be effectively applied to rapid and efficient identification of motherwort drugs.

The present invention discloses a culture medium for improving the activity of DC cells in patients with multiple myeloma and a culture method thereof, belonging to the field of biomedicine technology. The culture medium comprises RPMI 1640 culture medium and leonurine. When DC cells are cultured in vitro, the method significantly improves the activity and maturity of DC cells in healthy individuals and patients with multiple myeloma by adding an appropriate amount of leonurine, demonstrating its potential as a DC adjuvant and can be used in DC-based treatment strategies, such as DC vaccines and DC cell therapies.

The invention relates to the field of traditional Chinese medicine modern pharmacy, and discloses application of leonurine in preparation of a product for regulating sebum secretion of sebaceous gland cells, and the product for regulating sebum secretion of sebaceous gland cells comprises a sebum overflow disease medicine composition and an oil-control skin care product composition. The traditional Chinese medicine is expected to serve as a safe, effective and long-term-maintenance new treatment mode for sebum overflow diseases. The leonurine can inhibit the synthesis of sebum by inhibiting the gene transcription level and protein expression level of SREBP1 and FASN, thereby playing a role in treating sebum overflow diseases such as seborrheic dermatitis, acne and the like.

The invention relates to the technical field of preparation of feed additives, in particular to a feed additive for preventing fatty liver of lateolabrax japonicus. The composition comprises the following components in percentage by mass: 35-45% of yeast hydrolysate, 15-25% of curcumin, 15-25% of leonurine and the balance of a carrier, the carrier is defatted rice bran and / or rice hull powder; leonurine is one of active alkaloids in motherwort and has the functions of resisting atherosclerosis, resisting oxidation, protecting blood-brain barriers and the like, and traditional Chinese medicines have the advantages of relieving the liver damage degree, slowing down disease progression and removing toxic substances in the aspect of treating the injured liver diseases; the leonurine is selected as the perch feed for the first time and can effectively protect the liver and repair the liver injury, so that the occurrence of the micropterus salmoides fatty liver is prevented.

The present invention relates to the detection of leonurine. The present invention provides a method for detecting leonurine. A sample to be tested is dissolved in a 50-90% methanol aqueous solution, and synchronous fluorescence analysis is used. A Stokes shift of 25-35 nm and an emission wavelength of 300-310 nm are set to detect the fluorescence intensity of the test solution to qualitatively detect the leonurine component. The present invention has the following advantages: synchronous fluorescence analysis is used for determination, which is simple to operate, can quickly respond to leonurine, has high sensitivity and strong anti-interference ability, uses optimized measurement parameters for emission wavelength and Stokes shift, improves measurement selectivity, has high linearity of the standard curve equation, has a low detection limit, is fast to identify, and has accurate detection results, and has good development and application prospects.

The invention provides a method for increasing the number and activity of cell mitochondria by using leonurine. The method comprises the following steps: (1) selecting active ingredients; (2) processing concentration and time windows; (3) suitable cell types; and (4) detecting indexes and verifying a system. The number and activity of mitochondria are improved, after leonurine treatment, the number of cell mitochondria is increased, the mitochondrial membrane potential rises, the ATP generation level is improved, and the oxygen consumption rate is increased. According to the invention, the oxidative stress tolerance of the cells is enhanced, the treated cells are exposed in an anoxic (such as 0.1% oxygen) or oxidative stress environment, and the cell survival rate and function are obviously better than those of an untreated group.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

The application provides application of UGT5 genes and SCPL12 genes in production of agrostemma herb base in hairy roots. The application is realized by designing primer compositions to amplify the UGT5 genes and the SCPL12 genes, constructing a recombination carrier by using a Gateway technology, transforming the recombination carrier into Agrobacterium rhizogenes to obtain an Agrobacterium rhizogenes strain containing the UGT5 and the SCPL12, infecting leaves of Leonurus japonicus by using the Agrobacterium rhizogenes strain, culturing to obtain transgenic Leonurus japonicus hairy roots, and further producing the agrostemma herb base in the hairy roots. The content of the agrostemma herb base in the hairy roots of Leonurus japonicus obtained by using the Agrobacterium rhizogenes mediation and simultaneously overexpressing the UGT5 and the SCPL12 is higher than that of a control group. The method lays a foundation for production of the agrostemma herb base in transgenic plant cells.

The invention discloses a swertia-based bacteriostatic composition and a preparation method and application thereof, and belongs to the technical field of bacteriostatic agents. Swertia is used as a main bacteriostatic component, and cross-linking of peptidoglycan of bacterial cell walls is inhibited, so that synthesis of the cell walls is destroyed, the integrity of the bacterial cell walls is destroyed, and the antibacterial effect is improved. Therefore, the growth and reproduction of the staphylococcus aureus are inhibited. Secondly, the false Chinese swertia herb and the leonurine are compounded, so that on one hand, the destructive effect on cell walls of the staphylococcus aureus is enhanced, and on the other hand, in the glycolysis process of the staphylococcus aureus, the false Chinese swertia herb and the leonurine synergistically have a remarkable inhibition effect on hexokinase; therefore, the effect of inhibiting the growth and reproduction of the staphylococcus aureus is achieved by interfering the metabolic process of bacteria. And the destructive effect on a staphylococcus aureus biological membrane is improved through the assistance of nicotinic acid, so that the inhibition effect on staphylococcus aureus is enhanced.

The present disclosure relates to a field of biomedical technology. Embodiments of the present disclosure provide a leonurine nanocomposite hydrogel and preparation method and application thereof, including: dissolving dopamine (DA) monomers and inducing oxidation and self-polymerization of the DA to obtain polydopamine (PDA) nanoparticles, grafting thiol polyethylene glycol folic acid (SH-PEG-FA) on a surface of the PDA nanoparticles to obtain folic acid polydopamine (FA-PDA) nanocarriers; loading a leonurine (Leon) using the FA-PDA nanocarriers of the step 1 to obtain FA-PDA@Leon; encapsulating the FA-PDA@Leon of the step 2 into a gel matrix to obtain gel@FA-PDA@Leon hydrogel.